临床医学
臨床醫學
림상의학
CLINICAL MEDICINE
2014年
12期
6-8
,共3页
邰国梅%蔡晶%成国建%赵季忠
邰國梅%蔡晶%成國建%趙季忠
태국매%채정%성국건%조계충
食管癌%周剂量同期放化疗%紫杉醇%奈达铂
食管癌%週劑量同期放化療%紫杉醇%奈達鉑
식관암%주제량동기방화료%자삼순%내체박
Esophageal cancer%Weekly concurrent chemoradiotherapy%Paclitaxel%Nedaplatin
目的:比较紫杉醇∕奈达铂方案(TN)与5_氟尿嘧啶∕顺铂(PF 方案)在中晚期食管癌周剂量同期放化疗中近期疗效。方法选择72例中晚期食管癌患者,配对分为 TN 方案同期放化疗组和 PF 方案同期放化疗组,分别于放疗结束时和放疗后3个月观察两组近期疗效。结果① TN 组和 PF 组放疗结束时有效率分别为88?89%和86?11%(p ﹦0?722),两组放疗后3个月的有效率分别为91?67%和69?44%(p ﹦0?017)。TN 组和 PF 组放疗结束时局部病灶完全缓解率分别为38?88%和25?00%(p ﹦0?206),两组放疗后3个月局部病灶完全缓解率分别为69?44%和44?44%(p ﹦0?032)。②TN 组外周神经炎、白细胞减少反应稍高,而对患者生活质量影响较低,且疲劳、恶心恶吐、食欲减退及腹泻、便秘等症状较 PF 组发生率低。结论 TN 方案同期放化疗与 PF 方案同期放化疗相比,放疗后3个月有效率和完全缓解率显著提高,不良反应明显降低,患者依从性明显提高,值得进一步研究。
目的:比較紫杉醇∕奈達鉑方案(TN)與5_氟尿嘧啶∕順鉑(PF 方案)在中晚期食管癌週劑量同期放化療中近期療效。方法選擇72例中晚期食管癌患者,配對分為 TN 方案同期放化療組和 PF 方案同期放化療組,分彆于放療結束時和放療後3箇月觀察兩組近期療效。結果① TN 組和 PF 組放療結束時有效率分彆為88?89%和86?11%(p ﹦0?722),兩組放療後3箇月的有效率分彆為91?67%和69?44%(p ﹦0?017)。TN 組和 PF 組放療結束時跼部病竈完全緩解率分彆為38?88%和25?00%(p ﹦0?206),兩組放療後3箇月跼部病竈完全緩解率分彆為69?44%和44?44%(p ﹦0?032)。②TN 組外週神經炎、白細胞減少反應稍高,而對患者生活質量影響較低,且疲勞、噁心噁吐、食欲減退及腹瀉、便祕等癥狀較 PF 組髮生率低。結論 TN 方案同期放化療與 PF 方案同期放化療相比,放療後3箇月有效率和完全緩解率顯著提高,不良反應明顯降低,患者依從性明顯提高,值得進一步研究。
목적:비교자삼순∕내체박방안(TN)여5_불뇨밀정∕순박(PF 방안)재중만기식관암주제량동기방화료중근기료효。방법선택72례중만기식관암환자,배대분위 TN 방안동기방화료조화 PF 방안동기방화료조,분별우방료결속시화방료후3개월관찰량조근기료효。결과① TN 조화 PF 조방료결속시유효솔분별위88?89%화86?11%(p ﹦0?722),량조방료후3개월적유효솔분별위91?67%화69?44%(p ﹦0?017)。TN 조화 PF 조방료결속시국부병조완전완해솔분별위38?88%화25?00%(p ﹦0?206),량조방료후3개월국부병조완전완해솔분별위69?44%화44?44%(p ﹦0?032)。②TN 조외주신경염、백세포감소반응초고,이대환자생활질량영향교저,차피로、악심악토、식욕감퇴급복사、편비등증상교 PF 조발생솔저。결론 TN 방안동기방화료여 PF 방안동기방화료상비,방료후3개월유효솔화완전완해솔현저제고,불량반응명현강저,환자의종성명현제고,치득진일보연구。
Objective To compare the short_term effects of Paclitaxel∕ Nedaplatin and Cisplatin∕ 5_Fu on weekly concomitant chemoradiotherapy of advanced esophageal cancer. Methods Thirty_six patients with advanced esophageal cancer were divided into TN group(radiation with weekly concurrent chemotherapy of Paclitaxel∕ Nedaplatin)and PF group(radiation with weekly concurrent chemotherapy of Cisplatin∕ 5_Fu). The short_term effects at the end of the radiotherapy and 3 months after radiotherapy were observed. Results ①At the end of radiotherapy,the overall response rate in TN group and in PF group was 88. 89% and 86. 11% . At 3 months after the end of radiotherapy,the overall response rate of the group and the PF group was 91. 67% and 69. 44% . The complete remisson rate of TN group and in PF group was 38. 88% and 25. 00% . The complete remission rate of two groups was 69. 44% and 44. 44%(p ﹦ 0. 032). ②Incidences of peripheral nerves toxicities and leucopenia in TN group were higher than those in PF group,while the patients’physical function,role function,emotional function,social function,general health status were better than those in PF group,and treatment symptoms such as fatigue,nausea,vomiting,anorexia and consti_pation in TN group were less frequent in TN group than in PF group. Conclusion At 3 months after radiotherapy,radiation with weekly concurrent chemotherapy of Paclitaxel∕ Nedaplatin significantly improves the overall responses and the complete remis_sions,and reduces the impacts on quality of life at the same time.